SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay … [Read more…]

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) it will discontinue the trial to focus resources on clinical development of VS-7375, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Regulatory Affairs in Asia Training Course (Mar 24th – Mar 26th, 2026)” training has been added to ResearchAndMarkets.com’s offering. The pharmaceutical market in Asia is growing at a rapid pace and presents both opportunities and challenges to those wishing to work in the region. Rather than a single market, Asia is a … [Read more…]

CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of “The 100 Most Influential People in Oncology in 2025.” Soon-Shiong is the company’s Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing … [Read more…]

DUBLIN–(BUSINESS WIRE)–“An Essential Overview of the Pharmaceutical and Biotech Industries Training Course (Mar 12, 2026)” has been added to ResearchAndMarkets.com’s offering. The pharmaceutical and biotechnology industries are both complex and developing at a rapid pace. This intensive one-day course will give you an invaluable overview, refresher and update on all the important aspects from discovery … [Read more…]

— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)” training has been added to ResearchAndMarkets.com’s offering. The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. … [Read more…]

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share. The reverse stock … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, Tirzepatide), Type (Patented, Biosimilars), Format (Single Dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) – Global Forecast to 2033” report has been added to ResearchAndMarkets.com’s offering. The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 … [Read more…]

CRISPR-GNDM® platform achieves potent and specific activation of LAMA1 with therapeutic benefit in preclinical models Favorable safety and pharmacodynamics demonstrated in non-human primates TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–#Crispr–Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been published … [Read more…]